KatarzynaBialasiewicz/iStock via Getty Images Verastem, Inc. (NASDAQ:VSTM) is a clinical-stage biopharmaceutical company that develops cancer treatments targeting the RAS/MAPK pathway. This cell growth modulator is useful for pancreatic, lung, colorectal, and low-grade serous ovarian cancers (LGSOC). The company's leading therapy combines Avutometinib and Defactinib, which offer complementary mechanisms of action to disrupt malignant cell growth and metastasis. Its leading indication is for recurrent LGSOC. ...